Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Items 901–1,000 of 1,002
A Proposal to Redefine Clinical Immunogenicity Assessment
Mytych, D. T., Hock, M. B., Kroenke, M. A., Jawa, V., Kaliyaperumal, A., & Zhou, Y. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0059-7 · Cited by 9
Thomas, P. W. A., Ferwerda, G., West, R. L., & Hoentjen, F. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa115 · Cited by 9
Transgenic goats producing an improved version of cetuximab in milk
Laible, G., Cole, S., Brophy, B., Maclean, P. H., Chen, L. H., Pollock, D. P., Cavacini, L. A., Fournier, N., de Romeuf, C., Masiello, N. C., et al. (2020) · FASEB BioAdvances · doi:10.1096/fba.2020-00059 · Cited by 10
LC-MS/MS in glycomics and glycoproteomics analyses
Goli, M., Yu, A., Cho, B. G., Gautam, S., Wang, J., Reyes, C. D. G., Jiang, P., Peng, W., & Mechref, Y. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821447-3.00005-6 · Cited by 11
Integration of Genomic Profiling and Organoid Development in Precision Oncology
Yoon, H., & Lee, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010216 · Cited by 11
Nakagawa, Y., Chinuki, Y., Ogino, R., Yamasaki, K., Aiba, S., Ugajin, T., Yokozeki, H., Kitamura, K., & Morita, E. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16570 · Cited by 9
Pedersen, H. S. T., Sørensen, J. A., Madsen, F., Linneberg, A. R., Leth-Møller, K., Vestergaard, C., & Thomsen, S. F. (2022) · Clinical and Translational Allergy · doi:10.1002/clt2.12199 · Cited by 9
Melo‐Braga, M. N., Carvalho, M. B., Ferreira, M. C. E., Lavinder, J. J., Abbasi, A., Palmisano, G., Thaysen‐Andersen, M., Sajadi, M. M., Ippolito, G. C., & Felicori, L. F. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128362 · Cited by 9
Alpha-gal syndrome: when treatment of hypovolemic shock can lead to anaphylaxis
Nalin, F., Scarmozzino, R., Arcolacı, A., Olivieri, B., Tommasi, M., Bonadonna, P., & Zanoni, G. (2024) · Allergologia et Immunopathologia · doi:10.15586/aei.v52i3.1082 · Cited by 10
Historique et description des principales allergies croisées
Dutau, G., & Rancé, F. (2009) · Revue française d'allergologie · doi:10.1016/j.reval.2009.01.005 · Cited by 9
Biomarkers for non-human primate Type-I hypersensitivity: Antigen-specific immunoglobulin E assays
Clark, D., Shiota, F., Forte, C. P., Narayanan, P. K., Mytych, D. T., & Hock, M. B. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.03.007 · Cited by 9
EGFR-directed antibodies increase the risk of severe infection in cancer patients
Altan, M., & Burtness, B. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0276-9 · Cited by 9
Using Quality by Design Principles in Setting a Control Strategy for Product Quality Attributes
Flynn, G. C., & Nyberg, G. B. (2014) · ACS symposium series · doi:10.1021/bk-2014-1176.ch005 · Cited by 11
Incidence and Management of Olaratumab Infusion-Related Reactions
Tine, B. A. V., Govindarajan, R., Attia, S., Somaiah, N., Barker, S. S., Shahir, A., Barrett, E., Lee, P., Wacheck, V., Ramage, S., et al. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00761 · Cited by 9
Analysis of Regulatory Guidance on Antidrug Antibody Testing for Therapeutic Protein Products
Bano, N., McKelvey, T. W., Spear, N., Yang, T., Shankar, G., & Schantz, A. (2019) · Bioanalysis · doi:10.4155/bio-2019-0241 · Cited by 9
Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody
Kernstock, R. M., Sperinde, G. V., Finco, D., Davis, R., & Montgomery, D. L. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00440-5 · Cited by 9
Skin testing and drug challenge in the evaluation of drug hypersensitivity reactions
Wolfson, A. R., & Banerji, A. (2021) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.200091 · Cited by 9
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
Gao, L., Lau, Y.-K., Wei, R., O’Brien, L. M., Long, A. J., Piao, Y., & Abada, P. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04223-9 · Cited by 9
Alpha-gal syndrome. Allergy to red meat and gelatin
Zurbano-Azqueta, L., Antón-Casas, E., Duque-Gómez, S., Jiménez-Gómez, I., Pellon, L. F., & López-Gutiérrez, J. (2021) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2021.06.005 · Cited by 13
The top 100 most cited articles in anaphylaxis: a bibliometric analysis
Song, Y., Zhang, L., Yang, Y., & Sun, J. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00890-5 · Cited by 10
Les anticorps monoclonaux : une avancée thérapeutique récente et majeure
Paintaud, G., Lejarre, F., Ternant, D., Goupille, P., & Watier, H. (2009) · Therapies · doi:10.2515/therapie/2009008 · Cited by 9
Characterization of Therapeutic Proteins
Struble, E. B., Kirschbaum, N., Liu, J., Marszal, E., & Shapiro, M. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2015_5005 · Cited by 10
Kattla, J. J., Struwe, W. B., Doherty, M., Adamczyk, B., Saldova, R., Rudd, P. M., & Campbell, M. P. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-088504-9.00230-0 · Cited by 9
Management of infusion reactions in clinical trials and beyond: the US and EU perspectives.
Cmelak, A. J., Lordick, F., Borner, M., Goldberg, R. M., & Saif, M. W. (2009) · PubMed · Cited by 9
Diagnostic and experimental food challenges in patients with nonimmediate reactions to food
Tripathi, A., Commins, S. P., Heymann, P. W., & Platts‐Mills, T. A. E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.032 · Cited by 9
Self-citationBast, R. C., Zalutsky, M. R., & Frankel, A. E. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm065 · Cited by 9
Filip, A. B., Mahmood, L. Z., Tilly, C., Foster, H. R., Jackson, F., Banner, W., Platts‐Mills, T. A. E., Wilson, J. M., Schoppee, P. D., Charlton, N. P., et al. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2025.06.618 · Cited by 8
Self-citationCetuximab Hypersensitivity in the Setting of Asymptomatic Alpha‐Gal Sensitization
Emerson, A. G., Mundy, L., Murphy, B. A., & Stone, C. A. (2025) · Head & Neck · doi:10.1002/hed.70030 · Cited by 8
Self-citationGlobal trend of food‐induced anaphylaxis: Up to date
Leung, A. S. Y., Estrada‐Reyes, E., Goto, K., Huang, C., Li, J. M., Nagarajan, S. A., Ranasinghe, T., Sato, S., Srisuwatchari, W., Zepeda-Ortega, B., et al. (2025) · Pediatric Allergy and Immunology · doi:10.1111/pai.70246 · Cited by 10
Purification and Characterization of Antibodies Directed against the α-Gal Epitope
Zappe, A., Rosenlöcher, J., Kohla, G., Hinderlich, S., & Parr, M. K. (2021) · BioChem · doi:10.3390/biochem1020008 · Cited by 9
Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist
Seghers, S., Teuwen, L.-A. M. N., Beyens, M. M. J., Blick, D. D., Sabato, V., Ebo, D. G., & Prenen, H. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102559 · Cited by 10
Alpha‐Gal Syndrome: An Underrated Serious Disease and a Potential Future Challenge
Zhan, M., Yin, J., Xu, T., & Wen, L. (2024) · Global Challenges · doi:10.1002/gch2.202300331 · Cited by 10
Sarsarshahi, S., Bhattacharya, S., Zacharias, Z. R., Kamel, E. S., Houtman, J. C. D., & Nejadnik, M. R. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103771 · Cited by 8
Spigel, D. R., Greco, F., Waterhouse, D. M., Shipley, D. L., Lane, C. M., Vázquez, E. R., Clark, B. L., Infante, J. R., Bendell, J. C., Burris, H. A., et al. (2010) · PubMed · Cited by 8
The glycan did it: how the α-gal story rescued carbohydrates for allergists — a US perspective
Commins, S. P., Jerath, M. R., & Platts‐Mills, T. A. E. (2016) · Allergo Journal · doi:10.1007/s15007-016-1043-8 · Cited by 9
Self-citationBioanalytical Method Validation Guidance Language and a Decade of Progress
Lowes, S., & Brown, M. (2019) · Bioanalysis · doi:10.4155/bio-2019-0051 · Cited by 8
Chamberlain, P., & Rup, B. J. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00443-2 · Cited by 8
Lessons in Innate and Allergic Immunity From Dust Mite Feces and Tick Bites
Keshavarz, B., Erickson, L. D., Platts‐Mills, T. A. E., & Wilson, J. M. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.692643 · Cited by 9
Self-citationDesensitization to drugs in children
Ensina, L. F., Félix, M. M. R., da Cunha, F. S., & Caubet, J. (2022) · Allergologia et Immunopathologia · doi:10.15586/aei.v50i2.539 · Cited by 8
Spearman, M. A., & Butler, M. (2014) · Cell engineering · doi:10.1007/978-3-319-10320-4_9 · Cited by 14
Burkhart, P. W. M. K. K. (2014) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000195 · Cited by 8
Postmortem detection of antibiotic-specific immunoglobulin E in the case of anaphylactic death
Takahashi, M., Kondo, T., Morichika, M., Kuse, A., Nakagawa, K., & Ueno, Y. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.04.025 · Cited by 8
Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: An Appalachian effect?
Adams, C. B., Street, D. S., Crass, M., & Bossaer, J. B. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215618771 · Cited by 9
Namba, C., Tohyama, M., Murakami, M., Yoshida, T., Ugumori, T., Hato, N., Tano, T., Hamakawa, H., Kojima, Y., Nishina, T., et al. (2018) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12016 · Cited by 8
Multiple drug allergies: Recommendations for perioperative management
Patil, S. S., Sun, L., Fox, C. J., Anthony, K. E., Anzalone, F. A., Fisher, P. M., Girma, B., Huang, G. J., Barsley, E. L., Cornett, E. M., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.05.004 · Cited by 8
Micro-Heterogeneity of Antibody Molecules
Mimura, Y., Saldova, R., Mimura‐Kimura, Y., Rudd, P. M., & Jefferis, R. (2021) · Experientia supplementum · doi:10.1007/978-3-030-76912-3_1 · Cited by 11
Lin, P.-H., Tseng, C.-L., Cheng, Y.-C., Ho, C.-H., Chen, S. C., Wang, Y., Liu, E. W., Issafras, H., & Jiang, W. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1988072 · Cited by 9
Heparin desensitisation prior to cardiopulmonary bypass in a patient with alpha‐gal allergy
McRae, A. S., Tidwell, W. P., Patel, S. R., & Lombard, F. W. (2022) · Anaesthesia Reports · doi:10.1002/anr3.12203 · Cited by 10
The Current State of Targeted Agents in Rectal Cancer
Kim, D. D., & Eng, C. (2012) · International Journal of Surgical Oncology · doi:10.1155/2012/406830 · Cited by 8
Behnken, H. N., Fellenberg, M., Kötzler, M. P., Jirmann, R., Nagel, T., & Meyer, B. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6241-y · Cited by 8
Stinchcombe, T. E., Bradford, D. S., Hensing, T. A., LaRocca, R. V., Saleh, M. N., Evans, T. L., BAKRI, K. M., & Socinski, M. A. (2009) · Cancer Investigation · doi:10.3109/07357900903286958 · Cited by 8
Ehmann, L. M., Heinemann, V., & Wollenberg, A. (2011) · Der Internist · doi:10.1007/s00108-011-2896-2 · Cited by 8
da Silva, E. G. M., & Castro, F. F. M. (2014) · Brazilian Journal of Allergy and Immunology (BJAI) · doi:10.5935/2318-5015.20140004 · Cited by 8
Gonçalves, J., de Brito, P. M., Batista, A., Feio, J., Machado, F., Aperta, J., Ascensão, I., Pires, V., de Oliveira, C. C. A. L., Pontes, R. A., et al. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12477 · Cited by 8
Mécanismes d’action et toxicités potentielles des anticorps monoclonaux
Bejan‐Angoulvant, T., & Alexandre, J. (2019) · médecine/sciences · doi:10.1051/medsci/2019208 · Cited by 8
Blessmann, J., Hanlodsomphou, S., Santisouk, B., Choumlivong, K., Soukhaphouvong, S., Chanthilat, P., Brockow, K., & Biedermann, T. (2020) · Toxicon X · doi:10.1016/j.toxcx.2020.100054 · Cited by 9
New drug therapies and their effect on the skin
Treudler, R. (2009) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2009.07139.x · Cited by 8
Urtikaria: Manchmal doch IgE-vermittelt?
Wieczorek, D., Langhorst, J., Kapp, A., & Wedi, B. (2013) · Der Hautarzt · doi:10.1007/s00105-013-2566-5 · Cited by 8
Ticked Off: Allergic Effector Cells in the Pathogenesis of Alpha-gal Syndrome
Kepley, C. L., Wang, Y., Yelton, A., Siebert, E., & Iweala, O. I. (2025) · Current Allergy and Asthma Reports · doi:10.1007/s11882-025-01237-2 · Cited by 7
Tick to table: a scoping review on the global impact of alpha-gal syndrome
Pickle, E. O., Dye‐Braumuller, K. C., Self, S. C. W., Commins, S. P., & Nolan, M. S. (2026) · Journal of Medical Entomology · doi:10.1093/jme/tjag040 · Cited by 7
Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics
Mastrangeli, R., Satwekar, A., & Bierau, H. (2023) · Molecules · doi:10.3390/molecules28083304 · Cited by 7
Hatfield, G., Tepliakova, L., Tran, J. P., Lu, H., Gilbert, M., & Tam, R. Y. (2023) · mAbs · doi:10.1080/19420862.2023.2239405 · Cited by 7
Stavraka, C., Chauhan, J., Crescioli, S., McSweeney, S. M., Pope, A., Gillett, C., Meo, A. D., Prassas, I., Laddach, R., Stoker, K., et al. (2025) · Allergy · doi:10.1111/all.16514 · Cited by 7
Monoclonal Antobodies: Application in Radiopharmacy
Ligiero, T. B., Albernaz, M. D. S., de Carvalho, S., de Oliveira, S. V., & Santos‐Oliveira, R. (2014) · Current Radiopharmaceuticals · doi:10.2174/1874471006666131119212015 · Cited by 7
Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas
Riccardo, F., Barutello, G., Petito, A., Tarone, L., Conti, L., Arigoni, M., Musiu, C., Izzo, S., Volante, M., Longo, D. L., et al. (2020) · Vaccines · doi:10.3390/vaccines8020166 · Cited by 7
Pöhler, A., Emrich, T., Jordan, G., Schäfer, M. K.-H., Stubenrauch, K., Staack, R. F., Zach, C., Meir, J., & Faigle, J. (2022) · Bioanalysis · doi:10.4155/bio-2022-0085 · Cited by 7
Lee, J. Y., Choi, J., Hwang, S., Hahm, S. H., & Ahn, Y. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911807 · Cited by 7
Haga, Y., Yamada, M., Fujii, R., Saichi, N., Yokokawa, T., Hama, T., Hayakawa, Y., & Ueda, K. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01721 · Cited by 7
Gene-edited pigs: a translational model for human food allergy against alpha-Gal and anaphylaxis
Wang, Y., Hils, M., Fischer, A., Wölbing, F., Biedermann, T., Schnieke, A., & Fischer, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1358178 · Cited by 9
Allergy in perioperative setting
Zhao, W. (2024) · Allergy medicine. · doi:10.1016/j.allmed.2024.100009 · Cited by 7
Almond, R., Flanagan, B., Kimber, I., & Dearman, R. J. (2012) · Toxicology · doi:10.1016/j.tox.2012.06.018 · Cited by 7
Human IgE Antibodies Against Cross-Reactive Carbohydrate Determinants
Hemmer, W. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0870-3_8 · Cited by 8
Bojanini, L., Morgenstern‐Kaplan, D., Carrillo‐Martin, I., Vanegas, Y. A. M., Cuervo‐Pardo, L., Zwiener, R. D., & Gonzalez‐Estrada, A. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.14011 · Cited by 7
Ahmed, S. S., Ahmed, M. M., Ishaq, A., Freer, M., Stebbings, R., & Dickinson, A. M. (2024) · Toxics · doi:10.3390/toxics12060401 · Cited by 7
Review: Medical treatment of advanced colorectal cancer in 2009
Grothey, A. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009343302 · Cited by 7
Évaluation et validation des tests diagnostiques dans le cadre du ciblage thérapeutique
Landais, P., Méresse, V., Ghislain, J.-C., Arnaud, O., Bibeau, F., Cellier, D., d’Enfert, J., Eberlé, F., Goestchel, A., Grognet, J., et al. (2009) · Therapies · doi:10.2515/therapie/2009027 · Cited by 7
Biotechnology-Derived Medicines: What are They? A Pharmacological and a Historical Perspective
de Mora, F., & Torres, R. (2010) · Journal of Generic Medicines The Business Journal for the Generic Medicines Sector · doi:10.1057/jgm.2010.10 · Cited by 7
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland
Beck, A., Hanala, S., & Reichert, J. M. (2009) · mAbs · doi:10.4161/mabs.1.2.7890 · Cited by 7
Early Characterization of Biosimilar Therapeutics
Gelzleichter, T. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00007-1 · Cited by 7
Metabolic engineering of CHO cells to prepare glycoproteins
Wang, Q., & Betenbaugh, M. J. (2018) · Emerging Topics in Life Sciences · doi:10.1042/etls20180056 · Cited by 7
Mammalian meat allergy emerges after tick bite: the alpha-gal syndrome
Altshuler, E., Kirkpatrick, J. D., Aryan, M., & Miralles, F. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-245488 · Cited by 7
Platts‐Mills, T. A. E. (2012) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000331802 · Cited by 7
Self-citationThe continuing effect of the discovery of IgE by Kimishige Ishizaka
Platts‐Mills, T. A. E. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.017 · Cited by 7
Self-citationKanzaki, K., Nakagomi, Y., Asami, Y., Honma, H., Yokoyama, Y., Seki, H., Imamine, T., Nanaumi, M., Izawa, T., Misawa, S., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18712 · Cited by 6
The ‘totality of evidence’ and ‘extrapolation’ of SB17, a ustekinumab biosimilar
Cheon, J. H., Ye, B. D., Armuzzi, A., Rieder, F., Girolomoni, G., Puig, L., Jung, H. J., & Feldman, S. R. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2508838 · Cited by 6
Yang, B. C., & Castells, M. (2024) · Allergy · doi:10.1111/all.16353 · Cited by 7
MS‐Based Glycome Characterization of Biotherapeutics With N‐ and O‐Glycosylation
Oh, M. J., Seo, Y., Seo, N., & An, H. J. (2025) · Mass Spectrometry Reviews · doi:10.1002/mas.21925 · Cited by 6
Environmental risk and Alpha-gal Syndrome (AGS) in the Mid-Atlantic United States
Hollingsworth, B., Wiener, M., Giandomenico, D., Commins, S. P., & Boyce, R. M. (2025) · PLOS Climate · doi:10.1371/journal.pclm.0000528 · Cited by 6
Alpha-gal allergy in a South Asian country
Dasanayake, D., Karunatilake, C., Karunaratne, C., Fernando, N., Iddagoda, J., & de Silva, R. (2025) · BMC Immunology · doi:10.1186/s12865-025-00717-4 · Cited by 7
Sempa, J., Brenes, P., Tegeler, A., Looper, J. T., Chao, M. D., & Park, Y. (2025) · Nutrients · doi:10.3390/nu17193043 · Cited by 6
How Innovative Technology Is Moving Biologics Into the 21st Century
Robinson, D. K., & Sethuraman, N. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.294 · Cited by 6
The glycan did it: how the α-gal story rescued carbohydrates for allergists — a US perspective
Commins, S. P., Jerath, M. R., & Platts‐Mills, T. A. E. (2016) · Allergo Journal International · doi:10.1007/s40629-016-0097-1 · Cited by 6
Self-citationComponent-resolved Diagnostics in Allergy Practice Focusing on Food Allergy: A Systematic Review
Moitra, S., Tripathi, S. K., Mukherjee, S., Samajdar, S. S., Ghosh, S., Munshi, S., & Vedanthan, P. K. (2023) · Bengal Physician Journal · doi:10.5005/jp-journals-10070-8016 · Cited by 6
Ren, W., Yang, L., Feng, J., Wang, S., Hu, Q., Liu, H., Zhang, J., Wang, Z., Yan, M., Yu, H., et al. (2023) · Analytical Biochemistry · doi:10.1016/j.ab.2023.115362 · Cited by 6
Mysterious Allergy Caused by Tick Bite: Alpha-Gal Syndrome
Nalçacı, M. (2024) · Turkish Journal of Parasitology · doi:10.4274/tpd.galenos.2024.97720 · Cited by 8
The Immunogenicity of Therapeutic Antibodies
Sauerborn, M. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch23 · Cited by 8
Spigel, D. R., Mekhail, T. M., Waterhouse, D. M., Hadley, T. J., Webb, C. D., Burris, H. A., Hainsworth, J. D., & Greco, F. A. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1344698 · Cited by 6
Schuyler, A. J., Tripathi, A., Workman, L. J., Wilson, J. M., Erwin, E. A., Lawrence, M. G., McGowan, E. C., Hamilton, R. G., & Platts‐Mills, T. A. E. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.10.037 · Cited by 6
Self-citationAlpha-Gal-Syndrom: Ein Überblick zum klinischen Bild und zu pathophysiologischen Konzepten
Fischer, J., Reepschläger, T., Schricker, T., & Raap, U. (2022) · Der Hautarzt · doi:10.1007/s00105-022-04943-4 · Cited by 6
Bonomo, P., Desideri, I., Mangoni, M., Saieva, C., Loi, M., Becherini, C., Cerbai, C., Ganovelli, M., Salvestrini, V., Stocchi, G., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.02.008 · Cited by 6
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.